- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00892463
Identifying Very Early Response to Seroquel Extended Release (XR) Augmentation for Major Depressive Disorder
July 27, 2011 updated by: Sunnybrook Health Sciences Centre
Enhanced Identification of Very Early Response to Seroquel XR Added to an Antidepressant for the Treatment of Major Depressive Disorder With or Without Generalized Anxiety Disorder
The proposed study is for a 6 week open-label clinical trial in which Seroquel XR is added to a selective serotonin reuptake inhibitor (SSRI) medication for the treatment of depressive and/or anxiety symptoms.
Each subject will self-report changes in symptoms, functional impairment, etc. on a twice daily basis using a handheld computer (HHC) that transmits real-time symptoms reports to a central database.
Each subject will be assessed in-person on a weekly or biweekly basis during the course of the study.
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Detailed Description
This study is a 6-week open-label clinical trial in which Seroquel XR is added to an antidepressant medication for the treatment of MDD with or without comorbid generalized anxiety disorder.
Patients who are currently experiencing a depressive episode that has not responded to an adequate trial of an antidepressant will be eligible to participate.
During the course of augmentation treatment with Seroquel XR, each subject will regularly enter information on symptom severity and functional impairment into their handheld computer, and this information will be wirelessly transmitted to a central database.
Study Type
Interventional
Enrollment (Actual)
26
Phase
- Phase 4
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Ontario
-
Toronto, Ontario, Canada, M4N 3M5
- Sunnybrook Health Sciences Centre
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 65 years (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Diagnosis of major depressive disorder, currently depressed with or without a comorbid generalized anxiety disorder as determined by DSM-IV diagnostic criteria (confirmed using the MINI)
- Outpatient status
- 17-item Hamilton Depression Rating Scale (HAM-D) score of ≥ 18
- Treatment with any of the following antidepressant medications for the past 4 weeks at a minimum therapeutic dose
Exclusion Criteria:
- Diagnosis of a past or current bipolar disorder
- Current psychotic symptoms
- Substance-induced mood disorder
- Substance or alcohol dependence
- Prominent current suicidal ideation as defined by a HAM-D item 3 (suicide item) score of ≥ 3
- Current treatment with more than one antidepressant medication
- Current treatment with an tricyclic (TCA) antidepressant or monoamine oxidase inhibitor (MAOI)
- A patient with Diabetes Mellitus (DM)
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
The QIDS-SR16 (Quick Inventory of Depressive Symptomatology - Self-report)
Time Frame: Once Daily for 6 weeks
|
Once Daily for 6 weeks
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
HADS (Hamilton Anxiety Depression Scale) VADIS
Time Frame: Once/twice Daily for 6 weeks
|
Once/twice Daily for 6 weeks
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Collaborators
Investigators
- Principal Investigator: Ayal Schaffer, MD, Sunnybrook Health Sciences Centre - University of Toronto
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
May 1, 2009
Primary Completion (Actual)
December 1, 2010
Study Completion (Actual)
December 1, 2010
Study Registration Dates
First Submitted
April 30, 2009
First Submitted That Met QC Criteria
May 1, 2009
First Posted (Estimate)
May 4, 2009
Study Record Updates
Last Update Posted (Estimate)
July 28, 2011
Last Update Submitted That Met QC Criteria
July 27, 2011
Last Verified
July 1, 2011
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Behavioral Symptoms
- Mental Disorders
- Pathologic Processes
- Mood Disorders
- Depression
- Depressive Disorder
- Disease
- Depressive Disorder, Major
- Physiological Effects of Drugs
- Central Nervous System Depressants
- Antipsychotic Agents
- Tranquilizing Agents
- Psychotropic Drugs
- Antidepressive Agents
- Quetiapine Fumarate
Other Study ID Numbers
- D1443L00072
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Depressive Disorder, Major
-
Shalvata Mental Health CenterUnknownMAjor Depressive DisorderIsrael
-
York UniversityCentre for Addiction and Mental HealthSuspendedDisorder, Major DepressiveCanada
-
Seasons Biotechnology (Taizhou) Co., Ltd.CompletedMajor Depressive Disorder (MDDIndia
-
Gangnam Severance HospitalCompletedMajor Depressive Disorder(MDD)Korea, Republic of
-
University College, LondonCompletedUnipolar Major Depressive DisorderUnited Kingdom
-
Fundació Institut de Recerca de l'Hospital de la...Fondo de Investigacion SanitariaUnknown
-
Seasons Biotechnology (Taizhou) Co., Ltd.CompletedMajor Depressive Disorder (MDD)India
-
Repurposed Therapeutics, Inc.Unknown
-
GlaxoSmithKlineCompletedMajor Depressive Disorder (MDD)United States
-
AccexibleRecruitingMajor Depressive Disorder (MDD)Spain
Clinical Trials on Quetiapine (Seroquel) XR
-
University Hospitals Cleveland Medical CenterNational Alliance for Research on Schizophrenia and Depression; AstraZenecaCompletedAnxiety Disorders | Anxiety | Bipolar Disorder | Substance Use DisordersUnited States
-
AstraZenecaCompleted
-
AstraZenecaCompletedSchizophreniaItaly, Germany, Austria, Spain, Denmark
-
Inje UniversityUnknownMajor Depressive DisorderKorea, Republic of
-
BC Women's Hospital & Health CentreCompletedPostpartum DepressionCanada
-
Severance HospitalUnknownSchizophrenia | Abnormal Mental StateKorea, Republic of
-
Indiana University School of MedicineAstraZenecaCompleted
-
AstraZenecaTerminated
-
Indiana UniversityAstraZenecaCompletedPanic DisorderUnited States
-
Bayside HealthAstraZenecaUnknownSchizophrenia | PsychosisAustralia